20 May 2016
DETAILS
Amyris, Inc.
and
South Korea-based CJ CheilJedang Corporation (“CJ”)
today announced that the companies
have signed a Memorandum of Understanding (MOU)
to support large-scale manufacturing of
Amyris’s farnesene in existing CJ facilities.
The arrangement described in the MOU
would enable Amyris to utilize CJ’s
state of the art manufacturing capacity
while minimizing the capital investment necessary
to support projected near- and mid-term demand
for product applications using farnesene.
The partnership is also expected to include
the opportunity for CJ Bio (division of CJ CheilJedang)
* to market select Amyris products in Asian markets
as well as the potential for
* Amyris to develop several products for CJ Bio.
The companies are targeting completing
a definitive agreement by the first week of August 2016.
John Melo,
President & CEO of Amyris
“We are very pleased with the innovative approach of
CJ CheilJedang, to support quickly ramping up
our farnesene capacity with minimal capital investment
and with the collaborative partnership
to market some of our products in Asia,”
“This partnership completes our commercialization strategy
by providing us the ability to meet our farnesene demand
from our current partners without new investment
from Amyris and underpins our expected capacity needs
to meet farnesene demand that would require building
3-4 new plants the size of our Brotas facility by 2020.
We are also pleased with the opportunity
to partner with CJ for sales efforts in Asia
and the potential to collaborate on new products
that meet the needs of their existing customers.”
Hang Duk Roh,
Head of CJ CheilJedang BIO
“We are excited to partner with Amyris and leverage
the world’s leading Industrial Biotechnologies
to support the growing bio economy in Asia,”
Contact:
Peter DeNardo
Director,
Investor Relations and Corporate Communications
investor@amyris.com
pr@amyris.com
WWW.CHEMWINFO.COM BY KHUN PHICHAI
